Bischlorethylnitrosurea en es it fr

Bischlorethylnitrosurea Brand names, Bischlorethylnitrosurea Analogs

Bischlorethylnitrosurea Brand Names Mixture

  • No information avaliable

Bischlorethylnitrosurea Chemical_Formula


Bischlorethylnitrosurea RX_link

Bischlorethylnitrosurea fda sheet

Bischlorethylnitrosurea msds (material safety sheet)

Bischlorethylnitrosurea MSDS

Bischlorethylnitrosurea Synthesis Reference

Johnston TP et al. J Med Chem 122:669-681(1963).

Bischlorethylnitrosurea Molecular Weight

214.049 g/mol

Bischlorethylnitrosurea Melting Point

31 oC

Bischlorethylnitrosurea H2O Solubility

< 0.1 g/100 mL at 18 °C

Bischlorethylnitrosurea State


Bischlorethylnitrosurea LogP


Bischlorethylnitrosurea Dosage Forms

Powder for solution; Wafer

Bischlorethylnitrosurea Indication

For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.

Bischlorethylnitrosurea Pharmacology

Carmustine is one of the nitrosoureas indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in treatment of brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas. Although it is generally agreed that carmustine alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins.

Bischlorethylnitrosurea Absorption

5 to 28% bioavailability

Bischlorethylnitrosurea side effects and Toxicity

The oral LD50s in rat and mouse are 20 mg/kg and 45 mg/kg, respectively. Side effects include leukopenia, thrombocytopenia, nausea. Toxic effects include pulmonary fibrosis (20-0%) and bone marrow toxicity.

Bischlorethylnitrosurea Patient Information

No information avaliable

Bischlorethylnitrosurea Organisms Affected

Humans and other mammals